Molecular Basis of Cytokine-Induced Clearance of HBV DNA
细胞因子诱导 HBV DNA 清除的分子基础
基本信息
- 批准号:6632345
- 负责人:
- 金额:$ 4.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-06-23 至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Adapted from the Investigator's abstract): Hepatitis B Virus (HBV) can establish either a chronic or acute infection in infected individuals. Although cytotoxic T-lymphocyte (CTL)-mediated killing of infected hepatocytes likely plays an important role in the outcome of infection, HBV replication and gene expression are also strongly inhibited by non-cytolytic mechanisms mediated by the cytokines interferon alpha/beta, interferon gamma, and tumor necrosis factor alpha. The cytokine-mediated inhibition of HBV replication is likely to be critically important for clearance of the virus while protecting the liver from extensive CTLmediated damage. Although it has been demonstrated that the cytokine-mediated inhibition of HBV replication occurs at the level of assembly or stability of viral pre-genomic RNA-containing capsids, the mechanism by which this process occurs and the cellular proteins involved have not been determined. The focus of this proposal is to identify cellular proteins that interact with HBV core antigen in a cytokine-regulated manner, and to determine the relevance of these interactions to the clearance of HBV replicative intermediates from infected cells.
描述:(改编自研究者的摘要):乙型肝炎病毒 (HBV) 可以在感染者中造成慢性或急性感染。尽管细胞毒性 T 淋巴细胞 (CTL) 介导的对感染肝细胞的杀伤可能在感染结果中发挥重要作用,但 HBV 复制和基因表达也受到细胞因子干扰素 α/β、干扰素 γ 和肿瘤坏死因子 α 介导的非细胞溶解机制的强烈抑制。细胞因子介导的 HBV 复制抑制可能对于病毒的清除至关重要,同时保护肝脏免受 CTL 介导的广泛损伤。尽管已经证明细胞因子介导的HBV复制抑制发生在含有病毒前基因组RNA的衣壳的组装或稳定性水平上,但该过程发生的机制以及所涉及的细胞蛋白尚未确定。该提案的重点是鉴定以细胞因子调节方式与 HBV 核心抗原相互作用的细胞蛋白,并确定这些相互作用与从感染细胞中清除 HBV 复制中间体的相关性。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
- DOI:10.1016/j.xphs.2021.10.009
- 发表时间:2022-03
- 期刊:
- 影响因子:3.8
- 作者:Perazzolo, Simone;Shireman, Laura M.;Shen, Danny D.;Ho, Rodney J. Y.
- 通讯作者:Ho, Rodney J. Y.
A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.
一种新的配方使 3-HIV 药物替诺福韦-拉米夫定-多替拉韦从短效注射剂转变为长效注射剂。
- DOI:10.1097/qad.0000000000003706
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Perazzolo,Simone;Stephen,ZacharyR;Eguchi,Masa;Xu,Xiaolin;DelleFratte,Rachele;Collier,AnnC;Melvin,AnnJ;Ho,RodneyJY
- 通讯作者:Ho,RodneyJY
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture.
- DOI:10.1016/j.xphs.2021.10.007
- 发表时间:2022-03
- 期刊:
- 影响因子:3.8
- 作者:Perazzolo, Simone;Shireman, Laura M.;Shen, Danny D.;Ho, Rodney J. Y.
- 通讯作者:Ho, Rodney J. Y.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL ROBEK其他文献
MICHAEL ROBEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL ROBEK', 18)}}的其他基金
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
基于 AAV 的慢性 HBV 感染小鼠模型中病毒持续存在的人类机制
- 批准号:
10057461 - 财政年份:2020
- 资助金额:
$ 4.64万 - 项目类别:
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
基于 AAV 的慢性 HBV 感染小鼠模型中病毒持续存在的人类机制
- 批准号:
10391508 - 财政年份:2020
- 资助金额:
$ 4.64万 - 项目类别:
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
基于 AAV 的慢性 HBV 感染小鼠模型中病毒持续存在的人类机制
- 批准号:
10614465 - 财政年份:2020
- 资助金额:
$ 4.64万 - 项目类别:
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
基于 AAV 的慢性 HBV 感染小鼠模型中病毒持续存在的人类机制
- 批准号:
10159211 - 财政年份:2020
- 资助金额:
$ 4.64万 - 项目类别:
A new humanized mouse model of chronic hepatitis B
一种新的慢性乙型肝炎人源化小鼠模型
- 批准号:
8707714 - 财政年份:2014
- 资助金额:
$ 4.64万 - 项目类别:
Enhancing Oncolytic Virotherapy with Type III Interferon
使用 III 型干扰素增强溶瘤病毒治疗
- 批准号:
8638209 - 财政年份:2013
- 资助金额:
$ 4.64万 - 项目类别:
ENHANCING ONCOLYTIC VIROTHERAPY WITH TYPE III INTERFERON
使用 III 型干扰素增强溶瘤病毒治疗
- 批准号:
8989222 - 财政年份:2013
- 资助金额:
$ 4.64万 - 项目类别:
2011 International Meeting on the Molecular Biology of Hepatitis B Viruses
2011年乙型肝炎病毒分子生物学国际会议
- 批准号:
8122011 - 财政年份:2011
- 资助金额:
$ 4.64万 - 项目类别:
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma
预防肝细胞癌的病毒疫苗载体
- 批准号:
7848367 - 财政年份:2008
- 资助金额:
$ 4.64万 - 项目类别:
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma
预防肝细胞癌的病毒疫苗载体
- 批准号:
7900191 - 财政年份:2008
- 资助金额:
$ 4.64万 - 项目类别: